What are ATRA and arsenic trioxide?
All-trans retinoic acid (ATRA), also called tretinoin, and arsenic trioxide (ATO) are the two medicines at the heart of modern treatment for acute promyelocytic leukaemia (APL). APL is a fast-growing subtype of acute myeloid leukaemia in which immature white blood cells, called promyelocytes, build up in the bone marrow and blood.
Without treatment, APL can cause life-threatening bleeding within days. Yet it is now one of the most curable leukaemias in adults. For most people, the combination of ATRA and ATO cures APL without conventional chemotherapy.
ATRA is a form of vitamin A taken as capsules. Arsenic trioxide is given as a drip into a vein. Together they target the faulty protein that drives APL, a striking example of a cancer treatment aimed at the root cause of the disease.
A brief history
APL was once feared as the most deadly form of acute leukaemia because of its severe bleeding. In the 1980s, doctors in Shanghai reported that ATRA could make APL cells mature. Arsenic, used in traditional Chinese medicine for centuries, was studied in Harbin and Shanghai in the 1990s and proved highly active. Combining the two was later shown in European trials to be even better than ATRA with chemotherapy.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Targeted therapy (differentiating agents) |
| Main use | Acute promyelocytic leukaemia with the PML-RARA fusion |
| How it is given | ATRA as capsules twice a day; ATO as a drip into a vein |
| Course length | Induction of about 1-2 months, then consolidation for around 7 months |
| Where | Hospital stay for induction; mostly outpatient visits later |
| Main risks | Differentiation syndrome, heart rhythm changes (QT prolongation), liver changes |
| Outlook | Cure in the large majority of people with standard-risk APL |
2. How it works
The faulty gene
In APL, part of chromosome 15 swaps places with part of chromosome 17. This creates a fusion gene called PML-RARA. The protein it makes blocks the normal maturing of white blood cells, so they get stuck at the promyelocyte stage and accumulate.
How the two drugs act
| Drug | Effect |
|---|---|
| ATRA | Binds the RARA part of the fusion protein, releasing the block so cells mature into normal neutrophils |
| Arsenic trioxide | Attaches to the PML part, leading to breakdown of the fusion protein; also pushes cells to mature and die |
Because the two drugs attack the fusion protein from different sides, together they destroy the leukaemia-driving protein and can clear the disease entirely. This is why the treatment is often called differentiation therapy: rather than poisoning dividing cells, it makes cancer cells grow up and die naturally.
3. Who it is for
Conditions treated
| Condition | Role of ATRA and ATO |
|---|---|
| Acute promyelocytic leukaemia | Standard treatment for newly diagnosed and relapsed disease |
| Acute myeloid leukaemia | APL is a subtype of AML; other types of AML are not treated this way |
Risk groups
| Risk group | Definition | Typical treatment |
|---|---|---|
| Standard (low or intermediate) risk | White cell count 10 x 10^9 per litre or below | ATRA plus ATO without chemotherapy |
| High risk | White cell count above 10 x 10^9 per litre | ATRA and ATO plus some chemotherapy (such as idarubicin) or gemtuzumab ozogamicin |
Why speed matters
APL is a medical emergency. If doctors suspect it, ATRA is usually started straight away, even before genetic confirmation, because it rapidly reduces the risk of bleeding. Most early deaths from APL happen in the first days, often before treatment begins.
The bleeding problem
APL cells release substances that switch on the clotting system throughout the body. This uses up platelets and clotting factors, so people can bleed easily into the skin, gums, gut or, most seriously, the brain. At the same time, small clots can form. Doctors call this coagulopathy, and correcting it with transfusions is as urgent as treating the leukaemia itself.
Special groups
| Group | Considerations |
|---|---|
| Children | ATRA and ATO are also used, with doses adjusted for size; headaches from ATRA may be more common |
| Older adults | Chemotherapy-free treatment is especially valuable because it is gentler on the bone marrow |
| Pregnancy | ATRA may harm the baby in early pregnancy and ATO is generally avoided; plans need expert input (Sanz et al., 2019) |
4. Before treatment
| Step | Why it is done |
|---|---|
| Blood film | Shows the characteristic abnormal promyelocytes |
| Clotting tests | APL often causes a dangerous clotting disorder |
| Bone marrow sample | Confirms the diagnosis |
| Genetic tests (PCR or FISH) | Detects PML-RARA |
| Heart tracing (ECG) | ATO can lengthen the QT interval |
| Blood salts | Potassium and magnesium must be kept normal |
| Pregnancy test | Both drugs can harm a developing baby |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Emergency start | ATRA capsules begun as soon as APL is suspected |
| 2. Supportive care | Platelet transfusions, plasma or fibrinogen to control bleeding |
| 3. Induction | ATRA plus daily ATO infusions until remission, usually in hospital |
| 4. Remission check | Bone marrow test after induction |
| 5. Consolidation | Courses of ATRA (2 weeks on, 2 weeks off) and ATO (several weeks on, several off) over months |
| 6. Molecular test | PCR for PML-RARA at the end of consolidation |
| 7. Follow-up | Regular blood counts and checks |
Hospital stay
Induction usually means several weeks in hospital, especially early on when bleeding and differentiation syndrome are most likely. Each ATO infusion takes about 2 hours. During consolidation, infusions can usually be given as an outpatient.
6. Side effects and risks
| Side effect | Cause | Notes |
|---|---|---|
| Differentiation syndrome | Both drugs | Fever, breathlessness, weight gain, fluid on the lungs; treated with steroids |
| High white cell count | Both drugs | Common early on; may need extra medicines |
| QT prolongation | ATO | Heart rhythm change; ECGs and blood salts monitored |
| Liver changes | Both drugs | Usually mild; may need dose pauses |
| Headache | ATRA | Common; occasionally raised pressure around the brain |
| Dry skin, lips and eyes | ATRA | Typical of vitamin A drugs |
| Tiredness and nausea | Both | Usually manageable |
| Tingling in hands and feet | ATO | Usually mild |
Differentiation syndrome
This is the most important side effect to know about. As leukaemia cells mature, they can release substances that cause inflammation in the lungs and other organs. A review describes symptoms that include breathlessness, unexplained fever, weight gain of over 5 kg, low blood pressure and kidney problems, and recommends starting steroids as soon as it is suspected (Stahl and Tallman, 2019). Stopping ATRA or ATO may be needed in severe cases.
7. Results and outlook
| Study | Main finding |
|---|---|
| APL0406, initial results (standard-risk APL) | All evaluable people given ATRA and ATO reached remission, and two-year event-free survival was 97% versus 86% with ATRA and chemotherapy (Lo-Coco et al., 2013) |
| APL0406, final results (276 adults) | At about 4 years, overall survival was 99% with ATRA and ATO compared with about 93% with ATRA and chemotherapy, with far fewer relapses (Platzbecker et al., 2017) |
| European LeukemiaNet recommendations | Supports ATRA and ATO as frontline therapy and highlights early death as a remaining challenge (Sanz et al., 2019) |
Why chemotherapy-free treatment matters
ATRA and ATO cause less damage to the bone marrow than chemotherapy, so there are fewer infections and fewer transfusions. In the APL0406 trial, two people in the chemotherapy group went on to develop a treatment-related blood disorder, a risk largely avoided with ATRA and ATO (Platzbecker et al., 2017).
8. Recovery and aftercare
After induction
| Tip | Why |
|---|---|
| Take ATRA capsules with food | Helps absorption |
| Report fever, breathlessness or rapid weight gain | Possible differentiation syndrome |
| Report palpitations or fainting | Possible heart rhythm problem |
| Avoid medicines that lengthen QT | Some antibiotics, anti-sickness and heart drugs |
| Moisturise skin and lips | Eases ATRA dryness |
| Use reliable contraception | Both drugs can harm a developing baby |
Life in hospital
Several weeks on a haematology ward can be tiring and isolating. Bring things that make the time pass, such as books, music or a tablet, and ask whether visitors are allowed. Many units have specialist nurses and psychologists who can support you and your family.
Eating well
Good nutrition helps recovery. Small, frequent meals can help if you feel sick, and your team may suggest food safety precautions while your blood counts are low. Avoid vitamin A supplements during ATRA treatment unless your team approves them.
Follow-up
| Check | Purpose |
|---|---|
| Blood counts | Recovery and early relapse detection |
| PCR for PML-RARA | Confirms molecular remission |
| ECG and blood salts | During ATO courses |
| Liver tests | During treatment |
Life after APL
Most people return to work, study and normal activities within months of finishing treatment. Relapse after ATRA and ATO is uncommon, and late effects are fewer than after chemotherapy. Some people experience tiredness or low mood after such a sudden, frightening diagnosis, and support from the haematology team or a psychologist can help.
Relapse
If APL returns, ATO-based treatment can usually bring a second remission. Some people then go on to an autologous stem cell transplant, using their own cells collected when no leukaemia can be detected. Donor (allogeneic) transplant is reserved for people whose disease remains detectable.
For family and friends
A diagnosis of APL often comes suddenly, sometimes after a person is rushed to hospital with bruising or bleeding. Family members may feel shocked and helpless during the first days. It can help to know that once the early period has passed, the outlook is usually very good. Practical help, such as managing household tasks or bringing meals, is often appreciated.
Returning to work and activities
Most people can plan a gradual return to work during or after consolidation. Energy usually improves steadily, although tiredness can persist for some months. Gentle exercise, such as walking, can speed recovery.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| ATRA plus chemotherapy (anthracycline) | When ATO is unavailable or unsuitable; also used in some high-risk regimens |
| Gemtuzumab ozogamicin | Added for high-risk disease in some protocols |
| Oral arsenic | Used in some countries as an alternative to the drip |
| Stem cell transplant | Relapsed disease |
| Clinical trials | Ongoing research in high-risk APL |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Isn’t arsenic a poison? | At high doses, yes; at carefully controlled medical doses, it is a highly effective medicine |
| Will I lose my hair? | Hair loss is uncommon without chemotherapy |
| Will I need a central line? | Often, as it makes daily infusions and blood tests easier |
| Will I need a transplant? | Not usually; transplant is mainly for relapse |
| Is APL inherited? | No, the gene change develops in the bone marrow during life |
| Can I have children afterwards? | ATRA and ATO are less harmful to fertility than chemotherapy; discuss plans with your team |
| Can APL be treated in pregnancy? | Yes, but drug choice depends on the stage of pregnancy and needs specialist care |
| Do I need to avoid anything while taking ATRA? | Avoid extra vitamin A supplements and check any new medicines with your pharmacist |
| How likely am I to be cured? | Most people with standard-risk APL are cured |
11. Questions to ask your care team
- Is my APL standard risk or high risk?
- Will I need any chemotherapy?
- How long will I be in hospital?
- What are the signs of differentiation syndrome?
- How will you check my heart during arsenic treatment?
- When will we know I am in molecular remission?
- What follow-up will I need after treatment?
Resources
- Lo-Coco, F. et al. (2013) ‘Retinoic acid and arsenic trioxide for acute promyelocytic leukemia’, New England Journal of Medicine, 369(2), pp. 111-121.
- Platzbecker, U. et al. (2017) ‘Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial’, Journal of Clinical Oncology, 35(6), pp. 605-612.
- Sanz, M.A. et al. (2019) ‘Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet’, Blood, 133(15), pp. 1630-1643.
- Stahl, M. and Tallman, M.S. (2019) ‘Differentiation syndrome in acute promyelocytic leukaemia’, British Journal of Haematology, 187(2), pp. 157-162.
- National Cancer Institute (2026) Acute Myeloid Leukemia Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/leukemia/hp/adult-aml-treatment-pdq (Accessed: October 2026).
- National Cancer Institute (2026) Arsenic Trioxide. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/arsenictrioxide (Accessed: October 2026).
Prepared by the editorial team, October 2026.